Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custirsen + Docetaxel vs Docetaxel in Second-Line Advanced NSCLC
NCT01630733Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2012
- Primary completion
- Nov 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of custirsen in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Achieve Life Sciences. Primary endpoints: Overall Survival at 1331 days and Overall Survival: Stratified by Histology at 1331 days. Started Oct 2012; status: completed.
02
Drugs
custirsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01630733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630733.